Intrinsic value of Akorn - AKRX

Previous Close

$33.45

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$33.45

 
Intrinsic value

$23.09

 
Up/down potential

-31%

 
Rating

sell

 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of AKRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 4.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  13.40
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  1,117
  1,139
  1,166
  1,195
  1,229
  1,266
  1,307
  1,352
  1,400
  1,452
  1,508
  1,567
  1,631
  1,699
  1,771
  1,847
  1,928
  2,014
  2,104
  2,200
  2,301
  2,408
  2,520
  2,639
  2,764
  2,895
  3,034
  3,179
  3,333
  3,494
  3,664
Variable operating expenses, $m
 
  797
  815
  835
  858
  883
  910
  940
  973
  1,008
  1,045
  1,057
  1,100
  1,146
  1,194
  1,246
  1,300
  1,358
  1,419
  1,484
  1,552
  1,624
  1,700
  1,780
  1,864
  1,953
  2,046
  2,145
  2,248
  2,357
  2,472
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  789
  797
  815
  835
  858
  883
  910
  940
  973
  1,008
  1,045
  1,057
  1,100
  1,146
  1,194
  1,246
  1,300
  1,358
  1,419
  1,484
  1,552
  1,624
  1,700
  1,780
  1,864
  1,953
  2,046
  2,145
  2,248
  2,357
  2,472
Operating income, $m
  328
  342
  351
  361
  372
  384
  397
  412
  427
  444
  462
  510
  531
  553
  576
  601
  627
  655
  685
  716
  749
  783
  820
  859
  899
  942
  987
  1,035
  1,085
  1,137
  1,192
EBITDA, $m
  416
  441
  451
  463
  476
  490
  506
  523
  542
  562
  584
  607
  632
  658
  686
  715
  747
  780
  815
  852
  891
  932
  976
  1,022
  1,070
  1,121
  1,175
  1,231
  1,291
  1,353
  1,419
Interest expense (income), $m
  44
  38
  39
  40
  42
  44
  45
  47
  50
  52
  54
  57
  60
  63
  66
  70
  74
  78
  82
  86
  91
  96
  101
  106
  112
  118
  125
  131
  138
  146
  154
Earnings before tax, $m
  271
  304
  312
  320
  330
  340
  352
  364
  378
  392
  408
  453
  471
  490
  510
  531
  554
  578
  603
  630
  658
  688
  719
  752
  787
  824
  863
  903
  946
  991
  1,039
Tax expense, $m
  87
  82
  84
  86
  89
  92
  95
  98
  102
  106
  110
  122
  127
  132
  138
  143
  150
  156
  163
  170
  178
  186
  194
  203
  213
  222
  233
  244
  255
  268
  280
Net income, $m
  184
  222
  228
  234
  241
  248
  257
  266
  276
  286
  298
  331
  344
  357
  372
  388
  404
  422
  440
  460
  480
  502
  525
  549
  575
  601
  630
  659
  691
  724
  758

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  202
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,974
  1,808
  1,850
  1,898
  1,951
  2,010
  2,075
  2,146
  2,222
  2,305
  2,393
  2,488
  2,589
  2,696
  2,810
  2,932
  3,060
  3,196
  3,340
  3,492
  3,652
  3,822
  4,000
  4,188
  4,387
  4,595
  4,815
  5,047
  5,290
  5,547
  5,816
Adjusted assets (=assets-cash), $m
  1,772
  1,808
  1,850
  1,898
  1,951
  2,010
  2,075
  2,146
  2,222
  2,305
  2,393
  2,488
  2,589
  2,696
  2,810
  2,932
  3,060
  3,196
  3,340
  3,492
  3,652
  3,822
  4,000
  4,188
  4,387
  4,595
  4,815
  5,047
  5,290
  5,547
  5,816
Revenue / Adjusted assets
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
Average production assets, $m
  1,022
  1,042
  1,066
  1,094
  1,125
  1,159
  1,196
  1,237
  1,281
  1,329
  1,379
  1,434
  1,492
  1,554
  1,620
  1,690
  1,764
  1,842
  1,925
  2,013
  2,105
  2,203
  2,306
  2,414
  2,529
  2,649
  2,776
  2,909
  3,050
  3,197
  3,353
Working capital, $m
  510
  314
  322
  330
  339
  350
  361
  373
  386
  401
  416
  433
  450
  469
  489
  510
  532
  556
  581
  607
  635
  665
  696
  728
  763
  799
  837
  878
  920
  964
  1,011
Total debt, $m
  810
  834
  861
  892
  927
  966
  1,008
  1,054
  1,104
  1,158
  1,215
  1,277
  1,343
  1,413
  1,487
  1,566
  1,650
  1,739
  1,833
  1,932
  2,036
  2,147
  2,263
  2,386
  2,515
  2,651
  2,795
  2,945
  3,104
  3,271
  3,447
Total liabilities, $m
  1,155
  1,179
  1,206
  1,237
  1,272
  1,311
  1,353
  1,399
  1,449
  1,503
  1,560
  1,622
  1,688
  1,758
  1,832
  1,911
  1,995
  2,084
  2,178
  2,277
  2,381
  2,492
  2,608
  2,731
  2,860
  2,996
  3,140
  3,290
  3,449
  3,616
  3,792
Total equity, $m
  819
  629
  644
  660
  679
  700
  722
  747
  773
  802
  833
  866
  901
  938
  978
  1,020
  1,065
  1,112
  1,162
  1,215
  1,271
  1,330
  1,392
  1,458
  1,527
  1,599
  1,676
  1,756
  1,841
  1,930
  2,024
Total liabilities and equity, $m
  1,974
  1,808
  1,850
  1,897
  1,951
  2,011
  2,075
  2,146
  2,222
  2,305
  2,393
  2,488
  2,589
  2,696
  2,810
  2,931
  3,060
  3,196
  3,340
  3,492
  3,652
  3,822
  4,000
  4,189
  4,387
  4,595
  4,816
  5,046
  5,290
  5,546
  5,816
Debt-to-equity ratio
  0.989
  1.330
  1.340
  1.350
  1.370
  1.380
  1.400
  1.410
  1.430
  1.440
  1.460
  1.480
  1.490
  1.510
  1.520
  1.540
  1.550
  1.560
  1.580
  1.590
  1.600
  1.610
  1.630
  1.640
  1.650
  1.660
  1.670
  1.680
  1.690
  1.690
  1.700
Adjusted equity ratio
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348
  0.348

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  184
  222
  228
  234
  241
  248
  257
  266
  276
  286
  298
  331
  344
  357
  372
  388
  404
  422
  440
  460
  480
  502
  525
  549
  575
  601
  630
  659
  691
  724
  758
Depreciation, amort., depletion, $m
  88
  99
  100
  102
  104
  107
  109
  112
  115
  118
  122
  97
  101
  105
  109
  114
  119
  124
  130
  136
  142
  149
  156
  163
  171
  179
  188
  197
  206
  216
  227
Funds from operations, $m
  30
  321
  328
  336
  345
  355
  366
  378
  391
  404
  419
  428
  444
  462
  482
  502
  523
  546
  570
  596
  623
  651
  681
  712
  746
  780
  817
  856
  897
  940
  985
Change in working capital, $m
  -138
  6
  7
  8
  9
  10
  11
  12
  13
  14
  15
  16
  18
  19
  20
  21
  22
  24
  25
  26
  28
  29
  31
  33
  34
  36
  38
  40
  42
  45
  47
Cash from operations, $m
  168
  291
  321
  328
  336
  345
  355
  366
  377
  390
  404
  411
  427
  444
  462
  481
  501
  523
  545
  569
  595
  622
  650
  680
  711
  744
  779
  816
  854
  895
  938
Maintenance CAPEX, $m
  0
  -69
  -70
  -72
  -74
  -76
  -78
  -81
  -84
  -87
  -90
  -93
  -97
  -101
  -105
  -109
  -114
  -119
  -124
  -130
  -136
  -142
  -149
  -156
  -163
  -171
  -179
  -188
  -197
  -206
  -216
New CAPEX, $m
  -79
  -21
  -24
  -27
  -31
  -34
  -37
  -41
  -44
  -48
  -51
  -55
  -58
  -62
  -66
  -70
  -74
  -78
  -83
  -88
  -92
  -98
  -103
  -108
  -114
  -120
  -127
  -133
  -140
  -148
  -155
Cash from investing activities, $m
  -73
  -90
  -94
  -99
  -105
  -110
  -115
  -122
  -128
  -135
  -141
  -148
  -155
  -163
  -171
  -179
  -188
  -197
  -207
  -218
  -228
  -240
  -252
  -264
  -277
  -291
  -306
  -321
  -337
  -354
  -371
Free cash flow, $m
  95
  201
  226
  228
  231
  235
  239
  244
  250
  256
  263
  263
  272
  281
  291
  301
  313
  325
  338
  352
  366
  382
  398
  415
  434
  453
  473
  495
  517
  541
  566
Issuance/(repayment) of debt, $m
  -200
  24
  27
  31
  35
  39
  42
  46
  50
  54
  58
  62
  66
  70
  74
  79
  84
  89
  94
  99
  105
  110
  116
  123
  129
  136
  143
  151
  159
  167
  176
Issuance/(repurchase) of shares, $m
  -35
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -240
  24
  27
  31
  35
  39
  42
  46
  50
  54
  58
  62
  66
  70
  74
  79
  84
  89
  94
  99
  105
  110
  116
  123
  129
  136
  143
  151
  159
  167
  176
Total cash flow (excl. dividends), $m
  -145
  225
  253
  259
  266
  273
  281
  290
  300
  310
  321
  325
  338
  351
  365
  381
  397
  414
  432
  451
  471
  492
  514
  538
  563
  589
  617
  646
  676
  708
  742
Retained Cash Flow (-), $m
  -197
  -12
  -14
  -17
  -19
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -35
  -37
  -40
  -42
  -45
  -47
  -50
  -53
  -56
  -59
  -62
  -65
  -69
  -73
  -77
  -81
  -85
  -89
  -94
Prev. year cash balance distribution, $m
 
  202
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  415
  239
  243
  247
  253
  259
  265
  273
  281
  290
  292
  302
  314
  326
  338
  352
  366
  382
  398
  415
  433
  452
  473
  494
  516
  540
  565
  591
  619
  648
Discount rate, %
 
  5.20
  5.46
  5.73
  6.02
  6.32
  6.64
  6.97
  7.32
  7.68
  8.07
  8.47
  8.89
  9.34
  9.81
  10.30
  10.81
  11.35
  11.92
  12.51
  13.14
  13.80
  14.49
  15.21
  15.97
  16.77
  17.61
  18.49
  19.41
  20.38
  21.40
PV of cash for distribution, $m
 
  395
  215
  205
  196
  186
  176
  166
  155
  144
  134
  119
  109
  98
  88
  78
  68
  59
  50
  42
  35
  29
  23
  18
  14
  11
  8
  6
  4
  3
  2
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals in the United States and internationally. It operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment markets generic and branded ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays. This segmentÂ’s generic products include Atropine Sulfate Ophthalmic Solution; Clobetasol Propionate Ointment; Dehydrated Alcohol Injection; Ephedrine Sulfate Injection; Hydralazine Hydrochloride Injection; Lidocaine Ointment; Methylene Blue Injection; Myorisan Soft Gelatin Capsules; Nembutal Sodium Solution; and Progesterone Capsules. The Consumer Health segment markets branded and private label animal health products, as well as OTC products for the treatment of dry eye under the TheraTears brand name. This segment also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement, as well as the Diabetic Tussin line of cough and cold products. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

FINANCIAL RATIOS  of  Akorn (AKRX)

Valuation Ratios
P/E Ratio 22.6
Price to Sales 3.7
Price to Book 5.1
Price to Tangible Book
Price to Cash Flow 24.8
Price to Free Cash Flow 46.8
Growth Rates
Sales Growth Rate 13.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 146.9%
Cap. Spend. - 3 Yr. Gr. Rate 45.8%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 98.9%
Total Debt to Equity 98.9%
Interest Coverage 7
Management Effectiveness
Return On Assets 10.6%
Ret/ On Assets - 3 Yr. Avg. 7.6%
Return On Total Capital 11.2%
Ret/ On T. Cap. - 3 Yr. Avg. 7.4%
Return On Equity 25.5%
Return On Equity - 3 Yr. Avg. 20.3%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 60.3%
Gross Margin - 3 Yr. Avg. 56%
EBITDA Margin 36.1%
EBITDA Margin - 3 Yr. Avg. 31.5%
Operating Margin 29.4%
Oper. Margin - 3 Yr. Avg. 24%
Pre-Tax Margin 24.3%
Pre-Tax Margin - 3 Yr. Avg. 17.4%
Net Profit Margin 16.5%
Net Profit Margin - 3 Yr. Avg. 11.4%
Effective Tax Rate 32.1%
Eff/ Tax Rate - 3 Yr. Avg. 37%
Payout Ratio 0%

AKRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AKRX stock intrinsic value calculation we used $1117 million for the last fiscal year's total revenue generated by Akorn. The default revenue input number comes from 2016 income statement of Akorn. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AKRX stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.2%, whose default value for AKRX is calculated based on our internal credit rating of Akorn, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Akorn.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AKRX stock the variable cost ratio is equal to 70%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for AKRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 4.7% for Akorn.

Corporate tax rate of 27% is the nominal tax rate for Akorn. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AKRX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AKRX are equal to 91.5%.

Life of production assets of 14.8 years is the average useful life of capital assets used in Akorn operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AKRX is equal to 27.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $819 million for Akorn - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 122.924 million for Akorn is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Akorn at the current share price and the inputted number of shares is $4.1 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
PFE Pfizer 33.92 29.51  hold
TLGT Teligent 7.89 10.80  buy
TXMD TherapeuticsMD 5.10 0.18  str.sell
JNJ Johnson&Johnso 123.47 95.01  sell
NVS Novartis ADR 77.03 35.44  str.sell
TARO Taro Pharmaceu 116.85 179.44  str.buy
AMPH Amphastar Phar 15.10 1.80  str.sell
VRX Valeant Pharma 9.25 11.64  hold

COMPANY NEWS

▶ Fresenius Kabi to Acquire Akorn   [04:58PM  Business Wire]
▶ 4 Stocks With Strong Technical Momentum   [Apr-21-17 08:40AM  Benzinga]
▶ Akorn Acquisition Talks Send Generic Drugmakers Into Orbit   [Apr-10-17 04:31PM  Investor's Business Daily]
▶ Akorn Takeover Talk Unsurprising   [01:00PM  Morningstar]
▶ Akorn Acquisition Talks Send Generic Drugmakers Into Orbit   [12:25PM  Investor's Business Daily]
▶ Story Stocks from Briefing.com   [11:26AM  Briefing.com]
▶ The Market In 5 Minutes   [09:15AM  Benzinga]
▶ [$$] Fresenius in Talks to Buy U.S. Drug Maker Akorn   [Apr-08-17 07:26AM  The Wall Street Journal]
▶ Akorn Launches To Six-Month High On Fresenius Takeover Rumor   [04:39PM  Investor's Business Daily]
▶ Why Valeant Just Popped   [01:41PM  Barrons.com]
▶ Is The Market Expensive? Buffett Says No   [Mar-20-17 02:55PM  Forbes]
▶ ETFs with exposure to Akorn, Inc. : March 6, 2017   [Mar-06-17 01:27PM  Capital Cube]
▶ Bullish and Bearish Reversals in the Market   [12:00PM  TheStreet.com]
▶ Akorn to Report Fourth Quarter and Full Year 2016 Results   [Feb-06-17 07:30AM  GlobeNewswire]
▶ Value Investing 2017: 3 Stocks to Put on Your Radar   [Jan-19-17 01:27PM  at Motley Fool]
▶ [$$] Akorn Is a Best Idea for 2017   [Dec-15-16 07:54AM  at Barrons.com]
▶ Why Baytex Energy, Akorn, and Alamos Gold Jumped Today   [Dec-12-16 05:52PM  at Motley Fool]
▶ Why Akorn, Inc. Shares Are Surging 10%   [03:04PM  at Motley Fool]
▶ 3 Reasons Akorn Inc. Could Fall   [10:35AM  at Motley Fool]
▶ 3 Reasons Akorn Inc. Stock Could Rise   [Dec-02-16 09:49AM  at Motley Fool]
▶ Akorn Launches Ibuprofen Oral Suspension   [Nov-29-16 07:30AM  GlobeNewswire]
▶ How Akorn, Inc. (AKRX) Stacks Up Against Its Peers   [Nov-26-16 05:49PM  at Insider Monkey]
▶ Drug Makers Sued for Price Collusion (NVS, TEVA)   [Nov-20-16 12:30PM  at Investopedia]
▶ Akorn 3Q Adjusted EPS Beats Street (AKRX)   [Nov-04-16 02:35PM  at Investopedia]
Stock chart of AKRX Financial statements of AKRX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.